Frontiers in Endocrinology,
Journal Year:
2024,
Volume and Issue:
15
Published: Sept. 30, 2024
Cardiovascular
disease
(CVD)
is
the
leading
cause
of
human
mortality
worldwide.
Despite
Western
medicine
having
made
encouraging
results
in
clinical
management
CVD,
morbidity,
mortality,
and
disability
rates
remain
high.
Modern
pharmacology
has
confirmed
that
traditional
Chinese
(TCM),
characterized
by
its
multi-component,
multi-target,
integrity,
plays
a
positive
important
role
prevention
treatment
various
CVDs
China,
which
notable
advantages
stabilizing
disease,
improving
heart
function,
enhancing
quality
life.
Importantly,
TCM
gradually
being
accepted
international
community
due
to
low
cost,
high
safety,
versatile
bioactivity,
toxicity.
Unfortunately,
comprehensive
studies
on
therapeutic
effect
CVD
mechanisms
are
very
limited,
may
restrict
application
CVD.
Therefore,
this
review
performed
analyze
pathogenesis
including
inflammatory
response,
oxidative
stress,
mitochondrial
dysfunction,
pyroptosis,
ferroptosis,
dysbiosis
gut
microbiota,
etc.
Moreover,
we
summarized
latest
progress
(formulas,
extracts,
compounds)
curing
according
published
literature
from
2018
2023,
as
well
evidence.
In
conclusion,
expected
provide
useful
information
reference
for
further
drug
development
Molecular Aspects of Medicine,
Journal Year:
2023,
Volume and Issue:
93, P. 101194 - 101194
Published: June 27, 2023
Heart
failure
is
a
leading
cause
of
mortality
and
hospitalization
worldwide.
Cardiac
fibrosis,
resulting
from
the
excessive
deposition
collagen
fibers,
common
feature
across
spectrum
conditions
converging
in
heart
failure.
Eventually,
either
reparative
or
reactive
nature,
long-term
cardiac
fibrosis
contributes
to
development
progression
associated
with
poor
clinical
outcomes.
Despite
this,
specific
antifibrotic
therapies
are
lacking,
making
an
urgent
unmet
medical
need.
In
this
context,
better
patient
phenotyping
needed
characterize
heterogenous
features
advance
toward
its
personalized
management.
review,
we
will
describe
different
phenotypes
focus
on
potential
usefulness
imaging
techniques
circulating
biomarkers
for
non-invasive
characterization
condition
tracking
impact.
We
also
recapitulate
effects
existing
non-heart
drugs
discuss
strategies
under
preclinical
targeting
activation
fibroblasts
at
levels,
as
well
additional
extracardiac
processes.
BMC Cardiovascular Disorders,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Jan. 3, 2024
Abstract
Background
Coronary
microembolization(CME)is
a
common
complication
in
acute
coronary
syndrome
and
percutaneous
intervention,
which
is
closely
related
to
poor
prognosis.
Pyroptosis,
as
an
inflammatory
programmed
cell
death,
has
been
found
be
associated
with
CME-induced
myocardial
injury.
Colchicine
(COL)
potential
benefits
artery
disease
due
its
anti-inflammatory
effect.
However,
the
role
of
colchicine
pyroptosis-related
cardiomyocyte
injury
unclear.
This
study
was
carried
out
explore
effects
mechanisms
on
pyroptosis
induced
by
CME.
Methods
The
CME
animal
model
constructed
injecting
microspheres
into
left
ventricle
Sprague-Dawley
rats,
(0.3
mg/kg)
pretreatment
seven
days
before
day
modeling
or
compound
C(CC)co-treatment
given
half
hour
modeling.
divided
4
groups:
Sham
group,
+
COL
CC
group
(10
rats
for
each
group).
Cardiac
function,
serum
markers,
histopathology,
indicators
were
used
evaluate
colchicine.
Results
improved
cardiac
dysfunction
reduced
main
manifestations
improvement
ventricular
systolic
decrease
microinfarction
area,
mRNA
protein
indexes
pyroptosis.
Mechanistically,
increased
phosphorylation
level
adenosine
monophosphate-activated
kinase
(AMPK),
promoted
expression
silent
information
regulation
T1
(SIRT1),
inhibited
NOD-like
receptor
pyrin
containing
3
(NLRP3)
reduce
after
co-treatment
COL,
effect
partially
reversed.
Conclusion
improves
inhibiting
through
AMPK/SIRT1/NLRP3
signaling
pathway.
Journal of the American Heart Association,
Journal Year:
2024,
Volume and Issue:
13(9)
Published: May 3, 2024
The
only
clinically
approved
drug
that
reduces
doxorubicin
cardiotoxicity
is
dexrazoxane,
but
its
application
limited
due
to
the
risk
of
secondary
malignancies.
So,
exploring
alternative
effective
molecules
attenuate
crucial.
Colchicine
a
safe
and
well-tolerated
helps
reduce
production
reactive
oxygen
species.
High
doses
colchicine
have
been
reported
block
fusion
autophagosomes
lysosomes
in
cancer
cells.
However,
impact
on
autophagy
activity
within
cardiomyocytes
remains
inadequately
elucidated.
Recent
studies
highlighted
beneficial
effects
patients
with
pericarditis,
postprocedural
atrial
fibrillation,
coronary
artery
disease.
It
ambiguous
how
regulates
autophagic
flux
doxorubicin-induced
heart
failure.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(10), P. 5372 - 5372
Published: May 14, 2024
Heart
failure
(HF)
poses
a
significant
world
health
challenge
due
to
the
increase
in
aging
population
and
advancements
cardiac
care.
In
pathophysiology
of
HF,
inflammasome
has
been
correlated
with
development,
progression,
complications
HF
disease.
Discovering
biomarkers
linked
inflammasomes
enhances
understanding
diagnosis
prognosis.
Directing
signaling
emerges
as
an
innovative
therapeutic
strategy
for
managing
HF.
The
present
review
aims
delve
into
this
inflammatory
cascade,
its
role
development
potential
biomarker,
well
prospects
modulating
approach
Frontiers in Cardiovascular Medicine,
Journal Year:
2023,
Volume and Issue:
10
Published: June 29, 2023
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
accounts
for
around
half
of
all
cases
heart
and
may
become
the
dominant
type
in
near
future.
Unlike
HF
reduced
there
are
few
evidence-based
treatment
strategies
available.
There
is
a
significant
unmet
need
new
to
improve
clinical
outcomes
HFpEF
patients.
Inflammation
widely
thought
play
key
role
pathophysiology
represent
viable
target.
In
this
review
focusing
predominantly
on
studies,
we
will
summarise
inflammation
discuss
potential
therapeutic
targeting
inflammation.
